Ergocristine

Ergocristine

SCHEMBL455906

CC(C)[C@@]1(NC(=O)[C@H]2C=C3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 11/20 1.00
MAPT P10636 10/20 1.00
MEN1 O00255 9/20 1.00
KMT2A Q03164 9/20 1.00
CYP2C19 P33261 9/20 1.00
KDM4E B2RXH2 7/20 1.00
ALDH1A1 P00352 6/20 1.00
ABCB1 P08183 6/20 1.00
HIF1A Q16665 5/20 1.00
HPGD P15428 5/20 1.00
HSD17B10 Q99714 4/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
THRB P10828 2/20 1.00
CYP3A4 P08684 10/20 0.86
USP2 O75604 5/20 0.86
ADRA2A P08913 5/20 0.86
DRD2 P14416 5/20 0.86
ADRA2B P18089 5/20 0.86
ADRA2C P18825 5/20 0.86
DRD1 P21728 5/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ergocristine SCHEMBL4947691 1.00 CYP2C9 (1.00) CYP2C9MAPTMEN1KMT2ACYP2C19
Ergocristine SCHEMBL30957132 1.00 CYP2C9 (1.00) CYP2C9MAPTMEN1KMT2ACYP2C19
Ergocristine SCHEMBL177877 1.00 CYP2C9 (1.00) CYP2C9MAPTMEN1KMT2ACYP2C19
Ergocristine SCHEMBL14029486 1.00 CYP2C9 (1.00) CYP2C9MAPTMEN1KMT2ACYP2C19
Ergocristine SCHEMBL20136277 0.98 CYP2C9 (0.96) CYP2C9MAPTMEN1KMT2ACYP2C19
Ergocristine SCHEMBL11081603 0.98 CYP2C9 (0.96) CYP2C9MAPTMEN1KMT2ACYP2C19
Ergocristine SCHEMBL18208064 0.98 CYP2C9 (0.96) CYP2C9MAPTMEN1KMT2ACYP2C19
Ergocristine SCHEMBL29386896 0.94 MAPT (0.89) CYP2C9MAPTMEN1KMT2ACYP2C19
Ergocryptine SCHEMBL78951 0.92 KDM4E (1.00) CYP2C9MAPTMEN1KMT2ACYP2C19
Ergocryptine SCHEMBL11034170 0.92 KDM4E (1.00) CYP2C9MAPTMEN1KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4674894-A2 COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES Hemoteq AG (DE) 2026-01-07 EP claimed
EP-4663688-A2 CROSSLINKERS Hemoteq AG (DE) 2025-12-17 EP claimed
EP-4620936-A1 PROCESS FOR THE PREPARATION OF N6-ISOTOPE-LABELED ERGOT ALKALOIDS, IN PARTICULAR LYSERGIC ACID AMIDES AND ERGOPEPTINES Bundesrepublik Deutschland, vertreten durch den Bundesminister für Wirtschaft und Klimaschutz, dieser vertreten durch den Präsidenten der (DE) 2025-09-24 EP claimed
EP-4220161-A1 A BUFFER SYSTEM FOR PARTICLE-BASED MULTIPLEXED IMMUNOASSAYS Bundesrepublik Deutschland, vertreten durch den Bundesminister für Wirtschaft und Energie (DE) 2023-08-02 EP claimed
EP-1881853-B1 ALL-OVER COATING OF VESSEL STENTS HEMOTEQ AG (DE) 2016-09-28 EP claimed
US-20150031719-A1 Topical Therapy for the Treatment of Migraines, Muscle Sprains, Muscle Spasms, Spasticity and Related Conditions AFGIN PHARMA LLC 2015-01-29 US claimed
US-8916227-B2 Coating of the entire surface of endoprostheses HEMOTEQ AG (DE) 2014-12-23 US claimed
US-8883830-B2 Topical therapy for the treatment of migraines, muscle sprains, muscle spasms, spasticity and related conditions Afgin Pharma LLC. (US) 2014-11-11 US claimed
US-20120114741-A1 TOPICAL THERAPY FOR THE TREATMENT OF MIGRANES, MUSCLE SPRAINS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS AFGIN PHARMA LLC (US) 2012-05-10 US claimed
US-20080199506-A1 Lattice or mesh-like structure; covering with thin film over interstices and supports with multilayer polymer HEMOTEQ AG (DE) 2008-08-21 US claimed
US-7229784-B2 Modulation of secondary metabolite production by zinc binuclear cluster proteins MICROBIA, INC. (US) 2007-06-12 US claimed
US-20070065463-A1 Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions AFGIN PHARMA LLC 2007-03-22 US claimed
EP-1644004-A2 TROPICAL THERAPY FOR THE TREATMENT OF MIGRAINES, MUSCLE SPRAINS, MUSCLE SPASM, SPASTICITY AND RELATED CONDITIONS Aung-din, Ronald (US) 2006-04-12 EP claimed
WO-2004112723-A2 TROPICAL THERAPY FOR THE TREATMENT OF MIGRAINES, MUSCLE SPRAINS, MUSCLE SPASM, SPASTICITY AND RELATED CONDITIONS AUNG-DIN RONALD (US) 2004-12-29 WO claimed
US-20040077039-A1 Modulation of secondary metabolite production by zinc binuclear... DSM IP ASSETS B.V. (NL) 2004-04-22 US claimed
EP-1409530-A2 MODULATION OF SECONDARY METABOLITE PRODUCTION BY ZINC BINUCLEAR CLUSTER PROTEINS Microbia, Inc. (US) 2004-04-21 EP claimed
WO-2002024865-A2 MODULATION OF SECONDARY METABOLITE PRODUCTION BY ZINC BINUCLEAR CLUSTER PROTEINS MICROBIA, INC. (US) 2002-03-28 WO claimed
US-5573776-A Oral osmotic device with hydrogel driving member ALZA CORPORATION (US) 1996-11-12 US claimed
US-5468486-A Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1995-11-21 US claimed
US-4440772-A Acid addition salts of dextrorotatory ergot alkaloids, a process for the preparation thereof as well as their use as medicines LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, N.SOL.O. (YU) 1984-04-03 US claimed